Could cuts to federal cancer research funding slow new treatments, disrupt clinical trials, and affect the care patients receive years from now?

In Money Matters Episode 349, Christopher Hensley speaks with Fumiko Chino, MD, FASCO, a cancer researcher and Associate Professor in Breast Radiation Oncology at The University of Texas MD Anderson Cancer Center.

Recorded amid debate over a proposed reduction in National Institutes of Health funding for Fiscal Year 2027, this conversation explores how federal research investment reaches patients—from foundational discoveries and clinical trials to new treatments, improved survival, and better quality of life.

Dr. Chino also shares the personal loss that inspired her work and explains why cancer research is about more than laboratory discoveries. It is also connected to health care access, medical debt, financial toxicity, rural communities, and whether every patient can benefit from the next breakthrough.

In this episode:

• How NIH and NCI funding translates into patient care
• Why research interruptions may affect treatments years into the future
• What funding uncertainty can mean for clinical trials
• The potential impact on researchers and young scientists
• Medical debt and the financial burden of cancer
• Access challenges in rural and underserved communities
• Why cancer research should be viewed as a long-term investment
• How patients and families can make their voices heard

Learn more and support federal cancer research:

ASCO — Save Research. Stop Cancer:
https://www.asco.org/get-involved/advocacy/advocacy-agenda-initiatives/federally-funded-cancer-research/save-research

Dr. Fumiko Chino — MD Anderson faculty profile:
https://faculty.mdanderson.org/profiles/fumiko_chino.html

Money Matters is hosted by Christopher Hensley, RICP®, CES®, and produced by Houston First Financial Group.

This conversation is provided for educational purposes and does not constitute medical, financial, or legal advice. The views expressed belong to the individual speakers.

#CancerResearch #CancerCare #NIH